Articles

Odronextamab Plus CHOP in First-Line DLBCL: Early Results From the OLYMPIA-3 Study

DLBCL Download: Emerging Insights From ASCO 2026

Odronextamab combined with CHOP shows high response rates in high-risk, frontline DLBCL, with manageable safety and low rates of severe immune toxicity. Read More ›

Tafasitamab Plus Lenalidomide and R-CHOP in High-Risk Newly Diagnosed DLBCL: Results From the Phase 3 frontMIND Study

DLBCL Download: Emerging Insights From ASCO 2026

Adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival in patients with high-risk, newly diagnosed DLBCL, with a generally manageable safety profile. Read More ›

Outcomes by LymphoMAP Archetypes in Untreated DLBCL: POLARIX

DLBCL Download: Emerging Insights From ASCO 2026

Pola-R-CHP shows consistent benefit across DLBCL microenvironment subtypes, with the strongest gains seen in the high-risk FMAC group. Read More ›

Videos

Imlunestrant, Alone or in Combination With Abemaciclib, Demonstrates Potential in Treating Advanced Breast Cancer

By Erica L. Mayer, MD, MPH

SABCS 2025 - ER+/HER2- Breast Cancer

In this video, Erica Mayer, MD, MPH, from Dana-Farber Cancer Institute in Boston, MA, reviews results from the EMBER-3 trial exploring imlunestrant, with and without abemaciclib, as a novel, all-oral, chemotherapy-free therapy in the treatment of patients with estrogen receptor–positive/HER2-negative breast cancer. Read More ›

Updated Efficacy Results From the Phase 3 EMBER-3 Trial: Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

SABCS 2025 - ER+/HER2- Breast Cancer

Updated results from the EMBER-3 trial highlight the potential of imlunestrant, alone or with abemaciclib, as a promising all-oral, chemotherapy-free therapy for advanced estrogen receptor−positive/HER2-negative breast cancer. Read More ›

ELAINE 3: Phase 3 Study of Lasofoxifene Plus Abemaciclib in ER-Positive/HER2-Negative Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

SABCS 2025 - ER+/HER2- Breast Cancer

The ELAINE 3 trial explores the potential of lasofoxifene plus abemaciclib to redefine treatment for ESR1-mutated, estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer after CDK4/6 inhibitor progression. Read More ›

Clinical and Biomarker Subgroup Analysis From the Phase 3 evERA Trial: Giredestrant Plus Everolimus in ER-Positive/HER2-Negative Advanced Breast Cancer After CDK4/6 Inhibitor Treatment

SABCS 2025 - ER+/HER2- Breast Cancer

The phase 3 evERA trial highlights giredestrant plus everolimus as an effective, all-oral therapy for estrogen receptor (ER)-positive/HER2-negative advanced breast cancer following CDK4/6 inhibitor progression. Read More ›

OPERA-02: Phase 3 Study of Palazestrant Plus Ribociclib Versus Letrozole Plus Ribociclib for 1L Treatment of ER-Positive/HER2-Negative Advanced Breast Cancer

SABCS 2025 - ER+/HER2- Breast Cancer

The OPERA-02 trial investigated the potential of palazestrant combined with ribociclib to redefine 1L treatment for estrogen receptor (ER)-positive/HER2-negative advanced breast cancer by targeting resistance mechanisms and improving outcomes. Read More ›

Advancing Treatment Strategies for HR-Positive Metastatic Breast Cancer

SABCS 2025 - ER+/HER2- Breast Cancer

Discover how groundbreaking therapies targeting ESR1 mutations are transforming the treatment landscape for hormone receptor–positive metastatic breast cancer. Read More ›

ctDNA Dynamics in ER-Positive/HER2-Negative Advanced Breast Cancer: Insights From the Phase 3 EMBER-3 Trial

SABCS 2025 - ER+/HER2- Breast Cancer

New insights from the EMBER-3 trial reveal how circulating tumor DNA dynamics can predict treatment efficacy, highlighting the benefits of imlunestrant alone and in combination with abemaciclib for advanced estrogen receptor–positive/HER2-negative breast cancer. Read More ›

Articles

Page 2 of 143